At EURETINA 2026, Elon van Dijk, MD, PhD, FEBOphth, reviewed trial evidence favouring half-dose PDT over micropulse laser and eplerenone for central serous chorioretinopathy.
Elon van Dijk, MD, PhD, FEBOphth
Advertisement
Articles by Elon van Dijk, MD, PhD, FEBOphth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: Uveitis or retinitis pigmentosa? Ester Carreño, MD, PhD, on mimics
2
EURETINA 2026: Retinal signs as diagnostic clues to systemic metabolic disease
3
EURETINA 2026: Gene therapy sessions to watch in Vienna
4
Gene therapy 4D-150 enters phase 3 in DME with 4SIGHT trial launch
5